From: LEF Email List1 [mailto:email@example.com]
Sent: Friday, April 07, 2000 6:22 PM
Subject: Life Extension Update 4-7-00
LEF Email List1 - http://www.lef.org
In This Issue 4-7-00: Life Extension Magazine---IS THE FDA IN CONTEMPT OF
COURT?, CELLULAR NUTRITION FOR VITALITY AND LONGEVITY; What's Hot!---NEW
RADIOTHERAPY TECHNIQUE HIGHLY SUCCESSFUL AGAINST CANCER, OLDER TEA
DRINKERS HAVE STRONGER BONES; Disease Therapy Protocols---HEPATITIS B,
HEPATITIS C; Product Of The Week---CURCUMIN.
LIFE EXTENSION MAGAZINE
IS THE FDA IN CONTEMPT OF COURT?
By William Faloon
The legal tide is turning against the FDA. A new lawsuit accuses the FDA
of committing acts that are contrary to a Federal Appellate Court ruling,
the United States Constitution, the Administrative Procedures Act, and a
law Congress enacted to protect the right of consumers to access dietary
supplements. This case seeks to hold FDA officials in contempt of court
for their unlawful conduct.
CELLULAR NUTRITION FOR VITALITY AND LONGEVITY
Vitality means energy plus resistance to stress. Cells produce energy
through a process called "cellular respiration." But oxidative stress
caused by free radicals can damage the cell and inactivate cellular
respiration. The cell therefore mobilizes an antioxidant defense system to
protect itself against oxidative assault.
Nature in her economy created one molecule to serve both purposes.
Bioenergetic fuel and master antioxidant, CoQ10 plays vital roles in both
cellular respiration and antioxidant defense.
NEW RADIOTHERAPY TECHNIQUE HIGHLY SUCCESSFUL AGAINST CANCER
The February 15 2000 issue of the Proceedings of the National Academy of
Sciences reported on a new proprietary radiotherapy technology that,
administered in one dose, cured implanted cancers in 28 out of 30 mice.
(Disappearance of the tumor with absence for one year was considered a
cure.) NewRx Corporation's scientists injected a radiotherapy drug and
targeting antibody separately at different times. The two drugs join at
the tumor where the antibody locates, limiting radiation exposure to
healthy tissue. The body promptly eliminates radiation that does not join
OLDER TEA DRINKERS HAVE STRONGER BONES
About 10 million Americans suffer from osteoporosis. Their bones become
porous and more prone to fractures. Another 18 million have low bone
density, putting them at increased risk for the painful and debilitating
disorder. High caffeine intake has been associated with decreasing bone
density. But a new British study, reported in the American Journal of
Clinical Nutrition, found that while tea contains caffeine, it also offers
DISEASE THERAPY PROTOCOLS
Hepatitis B is most commonly spread by physical contact with contaminated
blood as in the sharing of nonsterilized needles or by sexual relations.
Symptoms of hepatitis B range from loss of appetite, weakness, body aches,
nausea, vomiting, diarrhea, fever, hives, joint pains, yellowing of the
skin and eyes (jaundice), and dark urine, to a "unique" distaste for
tobacco. The latter symptom often characterizes a "full-blown" hepatitis
The protective role of selenium against hepatitis B viruses was reported
in early January of 1997 in the Journal Biological Trace Element Research.
The study reported that in areas of China with high rates of hepatitis B
and primary liver cancer, high levels of dietary selenium reduce
liver-cancer incidence and hepatitis B infection.
The hepatitis C virus does most of its damage by latching onto molecules
of iron and delivering massive free radical damage to liver cells. These
free radicals can mutate cellular DNA to cause hepatocellular carcinoma,
and they can kill large numbers of liver cells. Liver dysfunction wreaks
havoc throughout the body. Successful eradication of the hepatitis C virus
from the body requires that iron levels in the liver and blood be at very
low levels, and thus it can be said that high stores of iron in the liver
preclude successful therapy against the hepatitis C virus. It is mandatory
to reduce iron levels in the body before initiating treatment with
interferon-ribavirin combination therapy.
The FDA-approved therapy to treat hepatitis is a 6-month regimen of
injectable alpha-interferon. Hepatitis C patients exhibit, at best, only
a 20% response to treatment with alpha-interferon. (Initially, 40 to 50%
may have a response, but most relapse). When the antiviral drug ribavirin
is combined with interferon, the response rate improves two- to tenfold.
The standard regimen consists of 800 to 1200 mg a day of orally
administered ribavirin taken in 3 divided doses for 6 months (200 to 400
mg, 3 times a day). At this time, however, the FDA says that ribavirin can
be used only after a patient has already failed a 6-month regimen of
alpha-interferon therapy. The FDA's concern about ribavirin stems from the
appearance of anemia seen in 10% of treated patients. (The anemia
disappears after cessation of ribavirin therapy but could have a
deleterious effect upon already sick individuals.)
PRODUCT OF THE WEEK
Curcumin is a potent antioxidant with specific antiviral,
anti-inflammatory, anticancer and cholesterol-lowering effects.
Curcumin is especially recommended for hepatitis C patients. One study
found it to be more effective than green tea extract in suppressing viral
damage to liver cells. Curcumin induces cancer cell apoptosis. Apoptosis
can be defined simply as programmed cancer cell death. Cancer researchers
are focusing in on agents that induce apoptosis as the next generation of
cancer drugs. Many of the nutrients in the cancer treatment protocol such
as selenium, vitamin A, green tea and vitamin D3 induce apoptosis.
The most effective nutrient available to induce apoptosis may be curcumin.
Curcumin is an antioxidant extract from the spice turmeric that produces a
wide range of health benefits. Cancer patients should be taking 2000 mg to
4000 mg a day of curcumin extract with a heavy meal. In a wide range of
cancer cells, curcumin has been shown to induce cell shrinkage, chromatin
condensation, DNA fragmentation and block cellular signal transduction,
all of which are characteristics of apoptosis according to an article
published in the journal Nutrition and Cancer USA (26/1 1996).
Please Visit Our Web Site:
E-mail Update Editor
This archive was generated by hypermail 2b29 : Thu Jul 27 2000 - 14:09:33 MDT